Federal budget issues
2025 · 2nd Quarter (Apr 1 - June 30)
NOVARTIS
Filed by TARPLIN, DOWNS & YOUNG, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 21, 2025
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- TARPLIN, DOWNS & YOUNG, LLC
- Client
- NOVARTIS
- Filing UUID
- 400507df-925b-4b99-aaeb-0515f1a2087a
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
MINI Act, IRA, 340B, affordability, pharmaceutical innovation, transparency, intellectual property, PBMs, pharmaceutical pricing issues, drug shortages, genetically targeted therapies, EPIC Act, supply chain
bio pharmaceutical reimbursement issues, IRA
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.